Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Baselga

Showing results (41-50 of 126) with videos related to

Pageof 13
Sort By:
Investigational New Drugs|June 11, 2003
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinomaRobert J Motzer, Robert Amato, Mary Todd, et al.
British Journal of Cancer|February 10, 2017
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR<sup>+</sup>, HER2<sup>-</sup> advanced breast cancer: results from BOLERO-2Mary Ellen Moynahan, David Chen, Wei He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.
Cancer Cell|April 7, 2009
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastomaSilvia Peñuelas, Judit Anido, Rosa M Prieto-Sánchez, et al.
Cancer Research|July 14, 2021
Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug CombinationsJorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcomaBart C Kuenen, Jose Tabernero, Jose Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted deliveryJohn W Park, Keelung Hong, Dmitri B Kirpotin, et al.
Cancer Research|February 3, 2006
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktKathryn E O'Reilly, Fredi Rojo, Qing-Bai She, et al.
Pageof 13

Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Investigational New Drugs|June 11, 2003
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinomaRobert J Motzer, Robert Amato, Mary Todd, et al.
British Journal of Cancer|February 10, 2017
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR<sup>+</sup>, HER2<sup>-</sup> advanced breast cancer: results from BOLERO-2Mary Ellen Moynahan, David Chen, Wei He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.
Cancer Cell|April 7, 2009
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastomaSilvia Peñuelas, Judit Anido, Rosa M Prieto-Sánchez, et al.
Cancer Research|July 14, 2021
Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug CombinationsJorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcomaBart C Kuenen, Jose Tabernero, Jose Baselga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted deliveryJohn W Park, Keelung Hong, Dmitri B Kirpotin, et al.
Cancer Research|February 3, 2006
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktKathryn E O'Reilly, Fredi Rojo, Qing-Bai She, et al.
Pageof 13